| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharmaceutical company/National Institutes of Health [NIH]) | Year complete | Primary publication | Full study treatment protocol/patient disposition |
|---|---|---|---|---|---|
|
Protocol AC (Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema) |
270 | National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services (NCT03321513) | 2022 | Jhaveri CD, et al. N Engl J Med. 2022;387:692-703. https://www.nejm.org/doi/10.1056/NEJMoa2204225 |